Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment
T Yan, L Zhu, J Chen - Experimental Hematology & Oncology, 2023 - Springer
The past decade has witnessed ongoing progress in immune therapy to ameliorate human
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
health. As an emerging technique, chimeric antigen receptor (CAR) T-cell therapy has the …
Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology
K Watanabe, S Kuramitsu, AD Posey Jr… - Frontiers in …, 2018 - frontiersin.org
A major obstacle for chimeric antigen receptor (CAR) T cell therapy in solid tumors is the
lack of truly tumor-specific target antigens, which translates to the targeting of tumor …
lack of truly tumor-specific target antigens, which translates to the targeting of tumor …
Bright future or blind alley? CAR-T cell therapy for solid tumors
K Zhang, H Chen, F Li, S Huang, F Chen… - Frontiers in …, 2023 - frontiersin.org
Chimeric antigen receptor (CAR) T cells therapy has emerged as a significant breakthrough
in adoptive immunotherapy for hematological malignancies with FDA approval. However …
in adoptive immunotherapy for hematological malignancies with FDA approval. However …
Enhancing chimeric antigen receptor T-cell efficacy in solid tumors
Chimeric antigen receptor (CAR) T-cell therapy has been acclaimed as a revolution in
cancer treatment following the impressive results in hematologic malignancies …
cancer treatment following the impressive results in hematologic malignancies …
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
Recently, the US Food and Drug Administration (FDA) approved the first chimeric antigen
receptor T cell (CAR-T) therapy for the treatment CD19-positive B cell acute lymphoblastic …
receptor T cell (CAR-T) therapy for the treatment CD19-positive B cell acute lymphoblastic …
Obstacles and coping strategies of CAR-T cell immunotherapy in solid tumors
L Miao, Z Zhang, Z Ren, F Tang, Y Li - Frontiers in Immunology, 2021 - frontiersin.org
Chimeric antigen receptor (CAR) T-cell immunotherapy refers to an adoptive
immunotherapy that has rapidly developed in recent years. It is a novel type of treatment that …
immunotherapy that has rapidly developed in recent years. It is a novel type of treatment that …
The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
A Daei Sorkhabi, L Mohamed Khosroshahi… - Frontiers in …, 2023 - frontiersin.org
The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …
hematologic cancers have increased the previously unprecedented excitement to use this …
Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero?
P Safarzadeh Kozani, P Safarzadeh Kozani… - Frontiers in …, 2022 - frontiersin.org
Chimeric antigen receptor T-cells (CAR-Ts) are known as revolutionary living drugs that
have turned the tables of conventional cancer treatments in certain hematologic …
have turned the tables of conventional cancer treatments in certain hematologic …
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments
Traditional cancer treatments use nonspecific drugs and monoclonal antibodies to target
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
tumor cells. Chimeric antigen receptor (CAR)-T cell therapy, however, leverages the immune …
Engineering chimeric antigen receptor T cells for solid tumour therapy
Cell‐based immunotherapy, for example, chimeric antigen receptor T (CAR‐T) cell
immunotherapy, has revolutionized cancer treatment, particularly for blood cancers …
immunotherapy, has revolutionized cancer treatment, particularly for blood cancers …